Author’s response to reviews

Title: Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing’s disease: a case report

Authors:

Tomoko Takiguchi (tomoko.taki72@chiba-u.jp)
Hisashi Koide (hikoide2006@yahoo.co.jp; koideh@chiba-u.jp)
Hidekazu Nagano (naganoh@chiba-u.jp)
Akitoshi Nakayama (a-nakayama@chiba-u.jp)
Masanori Fujimori (fujimoto212@gmail.com)
Ai Tamura (tamtam714@gmail.com)
Eri Komai (erikaneko_medicine@yahoo.co.jp)
Akina Shiga (mathew.vivi@gmail.com)
Takashi Kono (ta32ranun@chiba-u.jp)
Seiichiro Higuchi (sei.higu@gmail.com)
Ikki Sakuma (sakumaik@yahoo.co.jp)
Naoko Hashimoto (nhashi@graduate.chiba-u.jp)
Sawako Suzuki (sawako0919yuka@gmail.com)
Yui Miyabayashi (m_yui_3918@yahoo.co.jp)
Norio Ishiwatari (noriw0130@chiba-u.jp)
Kentaro Horiguchi (ken1977hori@gmail.com)
Yukio Nakatani (nakatani@faculty.chiba-u.jp)
Koutaro Yokote (kyokote@faculty.chiba-u.jp)
Tomoaki Tanaka (tomoaki@staff.chiba-u.jp)

Version: 3 Date: 13 Aug 2017
Author’s response to reviews:

BMC Endocrine Disorders,

Dear Dr. Louise Symmons,

We would like to thank you for your important suggestions. Please find for your consideration of a revised version of our manuscript: BEND-D-17-00032R2, entitled "Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report" by Tomoko Takiguchi et al.

On the following pages please find our point-by-point responses to each comment. Please note that our revised manuscript is submitted as a clean copy without any tracked changes, colored or highlighted text according to your decision letter.

We now believe that the new revisions to the manuscript will be enough to address your concerns in an appropriate and satisfactory manner, and hope that our revised paper will be acceptable for publication in BMC Endocrine Disorders.

Sincerely yours,

Tomoaki Tanaka, corresponding author

Department of Molecular Diagnosis

Chiba University Graduate School of Medicine

1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.

Phone: +81-43-226-2094  Fax: +81-43-226-209

E-mail: tomoaki@restaff.chiba-u.jp
1. In the Ethics approval and consent to participate section we note that you state that patients of GH-producing adenoma, non-functioning adenoma and Cushing adenoma gave consent for the publication of this case report. Excluding the 45 year old patient in this case report we would not expect the other patients to provide consent for publication seeing as this case report does not contain any identifiers which compromise their anonymity. We would however, like to ask for clarification whether you obtained informed consent, written or verbal, from these patients for the use of their cells in your research and please clearly state this in the Ethics approval and consent to participate section. If the need for consent was waived by an IRB or is deemed unnecessary according to national regulations, please clearly state this, including the name of the IRB or a reference to the relevant legislation.

Reply: We apologize that the description regarding the ethics approval and consent to participate in the revised manuscript appeared to be unclear. We would like to clearly state this issue as described in the text of Ethics approval and consent to participate section. We added the sentences “Written informed consent was obtained from the patient of presented case for publication of this case report. We also obtained written informed consents from all patients of GH-producing adenoma including presented case, Non-functioning adenoma, and Cushing adenoma for the use of their cells and tissues in this research.” in Ethics approval and consent to participate section.

2. Thank you for clarifying that all treatments the patient received are considered standard care for their condition. Please could you provide a statement reflecting this in the Ethics approval and consent to participate section.

Reply: Yes, we agree and added the sentence “All treatments the patient received are considered standard care for their condition.” in Ethics approval and consent to participate section.